JP2018510917A5 - - Google Patents

Download PDF

Info

Publication number
JP2018510917A5
JP2018510917A5 JP2018504078A JP2018504078A JP2018510917A5 JP 2018510917 A5 JP2018510917 A5 JP 2018510917A5 JP 2018504078 A JP2018504078 A JP 2018504078A JP 2018504078 A JP2018504078 A JP 2018504078A JP 2018510917 A5 JP2018510917 A5 JP 2018510917A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
cancer
composition according
isoty
capcna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018504078A
Other languages
English (en)
Japanese (ja)
Other versions
JP6748704B2 (ja
JP2018510917A (ja
Filing date
Publication date
Priority claimed from US14/684,259 external-priority patent/US10420840B2/en
Application filed filed Critical
Publication of JP2018510917A publication Critical patent/JP2018510917A/ja
Publication of JP2018510917A5 publication Critical patent/JP2018510917A5/ja
Application granted granted Critical
Publication of JP6748704B2 publication Critical patent/JP6748704B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018504078A 2015-04-10 2016-04-08 抗癌治療剤 Active JP6748704B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/684,259 US10420840B2 (en) 2015-04-10 2015-04-10 Anticancer therapeutic agents
US14/684,259 2015-04-10
PCT/US2016/026619 WO2016164707A1 (en) 2015-04-10 2016-04-08 Anticancer therapeutic agents

Publications (3)

Publication Number Publication Date
JP2018510917A JP2018510917A (ja) 2018-04-19
JP2018510917A5 true JP2018510917A5 (enExample) 2019-05-09
JP6748704B2 JP6748704B2 (ja) 2020-09-02

Family

ID=57072079

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018504078A Active JP6748704B2 (ja) 2015-04-10 2016-04-08 抗癌治療剤

Country Status (12)

Country Link
US (1) US10420840B2 (enExample)
EP (2) EP3280261B1 (enExample)
JP (1) JP6748704B2 (enExample)
CN (1) CN107404876B (enExample)
AU (1) AU2016245886B2 (enExample)
BR (1) BR122023024844A2 (enExample)
CA (1) CA2978965C (enExample)
ES (1) ES2991018T3 (enExample)
FI (1) FI3878444T3 (enExample)
PL (2) PL3878444T3 (enExample)
PT (1) PT3878444T (enExample)
WO (1) WO2016164707A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023231620A1 (en) * 2022-03-07 2024-09-12 City Of Hope Pcna inhibitors and uses thereof
WO2025054318A1 (en) * 2023-09-06 2025-03-13 City Of Hope Pcna inhibitors and uses thereof
WO2025184571A1 (en) * 2024-03-01 2025-09-04 City Of Hope Pcna inhibitors for the treatment of myc family associated cancers

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627165A (en) 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
US20050037090A1 (en) 1998-12-23 2005-02-17 Mckearn John P. Combination therapy including a cyclooxygenase-2 inhibitor and an antineoplastic agent
WO2006116631A2 (en) 2005-04-27 2006-11-02 Indiana University Research And Technology Corporation Cancer specific pcna isoform binding antibodies and uses thereof
AU2006261856B2 (en) * 2005-06-27 2012-07-05 Indiana University Research And Technology Corporation csPCNA isoform modifications and uses thereof
EP1989225A2 (en) * 2006-02-17 2008-11-12 Indiana University Research and Technology Corporation Peptide based inhibition of capcna protein-protein interactions in cancer
US20090123487A1 (en) 2007-09-19 2009-05-14 Katia Rothhaar Precursors and enzymes associated with post translational modification of proteins implicated in isoform generation of PCNA
CA2709398C (en) 2007-12-14 2017-11-07 The Cleveland Clinic Foundation Use of stromal cell-derived factor 1 for promoting wound healing
GB0808282D0 (en) 2008-05-07 2008-06-11 Medical Res Council Compounds for use in stabilizing p53 mutants
WO2010011890A2 (en) * 2008-07-24 2010-01-28 Indiana University Research And Technology Corporation Cancer peptide therapeutics
US20120195978A1 (en) * 2009-10-07 2012-08-02 Indiana University Research And Technology Corpora Capcna peptide therapeutics for cancer
JP2014511839A (ja) * 2011-03-23 2014-05-19 インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレイション 抗癌治療薬
MX2021006326A (es) * 2015-09-17 2022-12-16 Inhibidores de pcna.

Similar Documents

Publication Publication Date Title
JP2015078230A5 (enExample)
JP2014221779A5 (enExample)
WO2014152389A8 (en) Imaging agent for detection of diseased cells
EA202090530A1 (ru) Производные 1-бензил-2-имино-4-фенил-5-оксоимидазолидина как ингибиторы протеазы вич
MX380928B (es) Inhibidores de kras g12c.
CN109415406A (zh) 羊毛甾醇前药化合物及其制备方法和应用
JP2013509429A5 (enExample)
MX2015012414A (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
JP2017524735A5 (enExample)
JP2012255026A5 (enExample)
JP2016501221A5 (enExample)
JP2016515561A5 (enExample)
EA201690848A1 (ru) Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4
MA37206B1 (fr) Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MX2024009886A (es) Derivados de quinolina como inhibidores de integrina alfa4beta7.
BR112012027743A2 (pt) ciclopropil dicarboxamidas e análogos exibindo atividades anticâncer e antiproliferativas
JP2019520343A5 (enExample)
JP2014508804A5 (enExample)
JP2017517565A5 (enExample)
JP2015516427A5 (enExample)
JO3619B1 (ar) صياغات مثبطة للمناعة
WO2016098054A9 (en) Processes for preparing oxathiazin-like compounds
RU2018101431A (ru) Ингибиторы индоламин-2,3-диоксигеназы
MX394624B (es) Inhibidores selectivos hdac6, métodos de preparación y aplicación de los mismos.
RU2017141536A (ru) Замещенные производные индол-5-ола и их терапевтические применения